Pfizer Adds Fort Dodge Products with Wyeth Aquisition

Cindy ZimmermanAnimal Health, Company Announcement, Fort Dodge Animal Health, Pfizer

A new Pfizer Animal Health was unveiled last week as Pfizer’s acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed.

pfizerThe acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to greatly diversify its U.S. portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine and poultry.

In the beef and dairy animal category, Pfizer is adding FACTREL® (gonadorelin hydrochloride) and the pioneer line of SYNOVEX® implants to its current cattle portfolio that includes DRAXXIN® (tulathromycin), DECTOMAX®, EXCEDE® (ceftiofur crystalline free acid), EXCENEL® (ceftiofur hydrochloride), BOVI-SHIELD ® GOLD, LUTALYSE® (dinoprost tromethamine), ORBESEAL®, and SPECTRAMAST® (ceftiofur hydrochloride). Pfizer Animal Genetics also continues to explore opportunities to apply genomics technology to livestock health and management solutions.